… across all therapeutic options has led to a critical gap in evidence to clearly define preferred
systemic therapy choice. Additionally, the rising cost of systemic therapies being evaluated …

… The therapeutic armamentarium for the treatment of metastatic renal cell carcinoma (mRCC)
is increasingly rich nowadays. The definition of a therapeutic algorithm is a crucial issue, …

Several molecular pathways are implicated in renal cell carcinoma (RCC) pathogenesis,
including von Hippel-Lindau (VHL) gene inactivation leading to vascular endothelial growth …

… Sequencing decisions in advanced renal cell carcinoma are likely to become more difficult
… lines of therapy. Approximately 70% of patients benefit from targeted therapy before …

… cell carcinoma (BCC) is the most common skin cancer in white skin individuals. The treatment
of choice is surgical excision, but several other therapeutic … other therapeutic choices are …

… without clear guidance on the optimal choice in second-line therapy. In phase III studies, both
… Instead, therapeutic planning requires us to take a long-term view of our patient’s treatment …

… results of studies of first-line therapy, and we provide expert opinion on the most appropriate
treatment choices for particular patient groups receiving first-line and second-line therapy. …

Merkel cell carcinoma (MCC) is a rare but highly aggressive neuroendocrine skin cancer
whose incidence has almost doubled in recent decades. Risk factors for MCC include age > 65 …

… Thus, the risk category of individual patients can help guide therapy choices. … achieve
response can be relevant in guiding therapy choice. Regimens that have achieved relatively short …

… cell types portend a favourable prognosis compared with ccRCC, metastatic nccRCC,
especially metastatic papillary RCC, is characterized by a resistance to systemic therapy and poor …